相似文献
1
Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
Leukemia. 2020 Nov;34(11):3064-3069. doi: 10.1038/s41375-020-0760-x. Epub 2020 Feb 26.
2
Editorial: Mouse Models of B Cell Malignancies.
Front Immunol. 2021 Oct 28;12:789901. doi: 10.3389/fimmu.2021.789901. eCollection 2021.
3
CD19 as an attractive target for antibody-based therapy.
MAbs. 2012 Sep-Oct;4(5):571-7. doi: 10.4161/mabs.21338. Epub 2012 Jul 23.
4
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Int J Mol Sci. 2019 May 18;20(10):2469. doi: 10.3390/ijms20102469.
5
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Ann Hematol. 2020 Oct;99(10):2215-2229. doi: 10.1007/s00277-020-04221-0. Epub 2020 Aug 27.
6
Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
Arch Iran Med. 2019 Jan 1;22(1):7-10.
7
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
8
[Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
Rinsho Ketsueki. 2016;57(11):2365-2372. doi: 10.11406/rinketsu.57.2365.
9
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Br J Haematol. 2011 Nov;155(4):426-37. doi: 10.1111/j.1365-2141.2011.08857.x. Epub 2011 Sep 9.
10
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
Leukemia. 2021 Jan;35(1):75-89. doi: 10.1038/s41375-020-0792-2. Epub 2020 Mar 24.
引用本文的文献
1
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.
Nat Commun. 2025 Apr 23;16(1):3800. doi: 10.1038/s41467-025-58868-2.
2
TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation.
Sci Adv. 2024 Sep 6;10(36):eadj4632. doi: 10.1126/sciadv.adj4632. Epub 2024 Sep 4.
3
Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.
Curr Treat Options Oncol. 2024 Aug;25(8):993-1010. doi: 10.1007/s11864-024-01213-4. Epub 2024 Jun 25.
4
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Clin Hematol Int. 2024 Mar 13;6(1):96-115. doi: 10.46989/001c.94386. eCollection 2024.
5
Standardization of flow cytometric detection of antigen expression.
Cytometry B Clin Cytom. 2024 Jan;106(1):25-34. doi: 10.1002/cyto.b.22155. Epub 2024 Jan 12.
6
A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia.
Blood Adv. 2023 Aug 8;7(15):4218-4232. doi: 10.1182/bloodadvances.2022008977.
7
Blinatumomab Prior to CAR-T Cell Therapy-A Treatment Option Worth Consideration for High Disease Burden.
Biomedicines. 2022 Nov 13;10(11):2915. doi: 10.3390/biomedicines10112915.
8
Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy.
Cancers (Basel). 2022 Nov 5;14(21):5445. doi: 10.3390/cancers14215445.
9
Emerging frontiers in immuno- and gene therapy for cancer.
Cytotherapy. 2023 Jan;25(1):20-32. doi: 10.1016/j.jcyt.2022.10.002. Epub 2022 Oct 22.
10
The CD19neg needle in the haystack.
Blood. 2022 Jul 7;140(1):4-6. doi: 10.1182/blood.2022016335.
Zotero 插件